The online version of this article (doi:10.1007/s13300-014-0079-6) contains supplementary material, which is available to authorized users.
Type 2 diabetes mellitus (T2DM) is an increasing problem worldwide and a leading risk factor for cardiovascular disease. As beta cell function declines, the management of T2DM typically comprises of escalations in treatment from diet and exercise to oral therapies and eventually insulin. Treatment algorithms based on the attainment of blood glucose targets may not account for changes in other cardiovascular risk factors. The objective of this study is to describe unmet clinical need, defined as failure to reduce weight or meet targets for blood pressure, total cholesterol or glycated hemoglobin (HbA1c) levels.
Anonymized UK patient data for those (1) initiating oral antidiabetic drug (OAD) monotherapy, (2) escalating to dual therapy, (3) escalating to triple therapy, and (4) escalating to insulin therapy over the study period (01/01/2005–31/12/2009) were obtained from The Health Improvement Network (THIN). Changes in risk factors were evaluated before and after therapy escalation, and the attainment of targets, assessed at the last recorded measurement, as follows: HbA1c <7.5%, systolic blood pressure (SBP) <140 mmHg, total cholesterol (TC) <5 mmol/L, and reduction in weight.
Prior to therapy escalation, mean HbA1c in each subgroup exceeded 7.5% and was higher respective to the number of OADs being used (monotherapy: 8.03%; double: 8.48%; triple: 8.71%). Insulin users displayed the highest HbA1c prior to treatment escalation (9.78%). Following escalation, a decline in HbA1c was observed in all subgroups. By contrast, mean SBP and TC levels decreased prior to the addition of a second and third oral therapy. Consistent improvements following treatment escalation were not observed across the other risk factors following therapy escalation. Overall, the proportion of subjects that attained all four targets ranged from 3% (monotherapy and insulin) to 6% (dual therapy).
The potential unmet clinical need among conventionally treated T2DM patients is significant, with respect to the control of blood glucose and other cardiovascular risk factors: SBP, TC, and weight. There clearly remains the need for new therapeutic approaches to alleviate the burden associated with T2DM.
American Diabetes Association, Lung National Heart, and Blood Institute, Juvenile Diabetes Foundation International, National Institute of Diabetes and Digestive and Kidney Diseases, American Heart Association. Diabetes mellitus: a major risk factor for cardiovascular disease. Circulation. 1999;100:1132–3.
Massó González EL, Johansson S, Wallander M-A, García Rodríguez LA. Trends in the prevalence and incidence of diabetes in the UK: 1996–2005. J Epidemiol Commun Health. 2009;63(4):332–6. CrossRef
National Institute for Health and Care Excellence. CG87. Type 2 diabetes—newer agents. 2009.
Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364–79. PubMedCentralPubMedCrossRef
Cegedim strategic data. The Health Improvement Network (THIN) database. 2014 Accessed.
National Institute for Health and Care Excellence. CG66. Type 2 diabetes—the management of type 2 diabetes. 2008.
StataCorp. Stata Statistical Software: release 13. 2013.
Food and drug administration. SOPP 8414: fast track drug development programs: designation and review programs. 2001. Available at http://www.fda.gov/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/proceduressopps/ucm073515.htm. Accessed August 2014.
Health and Social Care Information Centre. Quality and outcomes framework—2011–12, England level. 2012. Available at http://www.hscic.gov.uk/catalogue/PUB08661. Accessed August 2014.
StatsWales. Quality and outcomes framework. 2013. Available at https://statswales.wales.gov.uk/Catalogue/Health-and-Social-Care/NHS-Primary-and-Community-Activity/GMS-Contract. Accessed August 2014.
Kankeu HT, Saksena P, Xu K, Evans DB. The financial burden from non-communicable diseases in low- and middle-income countries: a literature review. Health Res Policy Syst/BioMed Central. 2013;11:31. CrossRef
NHS Diabetes. Report number 46357 Diabetes in the NHS, 2007. Published by the National Diabetes Support Team on behalf a group of diabetes specialists in England. 2007. Available at www.diabetes.nhs.uk/document.php?o=318. Accessed October 2011.
The NHS Information Centre. Prescribing for diabetes in England: 2005/6–2010/11. 2011. Available at http://www.ic.nhs.uk/webfiles/publications/prescribing%20diabetes%20200506%20to%20201011/Prescribing_for_Diabetes_in_England_20056_to_201011.pdf. Accessed October 2011.
- Assessment of Unmet Clinical Need in Type 2 Diabetic Patients on Conventional Therapy in the UK
- Springer Healthcare
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II